SNS-595

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2012
01220062012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
INTRODUCTION The antineoplastic quinolone derivative vosaroxin (SNS-595, Sunesis, South San Francisco, CA, USA) was first… (More)
Is this relevant?
2009
2009
(+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2008
2008
Voreloxin, formerly known as SNS-595 or AG-7352, is a novel naphthyridine analog currently under investigation for the treatment… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2008
Review
2008
Sunesis Pharmaceuticals Inc, under license from Dainippon Sumitomo Pharma Co Ltd, is developing SNS-595, a naphthyridine cell… (More)
Is this relevant?
Review
2007
Review
2007
The disease of cancer has been ranked second after cardiovascular diseases and plant-derived molecules have played an important… (More)
Is this relevant?
2006
2006
3062 Background: SNS-595 is a novel naphthyridine analog with broad and potent activity in preclinical models. METHODS SNS-595… (More)
Is this relevant?